SEARCH

SEARCH BY CITATION

References

  • 1
    Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 22232.
  • 2
    Mahaut-Smith MP, Ennion SJ, Rolf MG, Evans RJ. ADP is not an agonist at P2X (1) receptors. evidence for separate receptors stimulated by ATP and ADP on human platelets. Br J Pharmacol 2000; 131: 10814.
  • 3
    Rolf MG, Brearley CA, Mahaut-Smith MP. Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP. Thromb Haemost 2001; 85: 3038.
  • 4
    Hechler B, Lenain N, Marchese P, Vial C, Heim V, Freund M, Cazenave JP, Cattaneo M, Ruggeri ZM, Evans R, Gachet C. A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J Exp Med 2003; 198: 6617.DOI: 10.1084/jem.20030144
  • 5
    Oury C, Kuijpers MJ, Toth-Zsamboki E, Bonnefoy A, Danloy S, Vreys I, Feijge MA, De Vos R, Vermylen J, Heemskerk JW, Hoylaerts MF. Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood 2003; 101: 396976.
  • 6
    Oury C, Toth-Zsamboki E, Thys C, Tytgat J, Vermylen J, Hoylaerts MF. The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb Haemost 2001; 86: 126471.
  • 7
    Hechler B, Leon C, Vial C, Vigne P, Frelin C, Cazenave JP, Gachet C. The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood 1998; 92: 1529.
  • 8
    Leon C, Freund M, Ravanat C, Baurand A, Cazenave JP, Gachet C. Key role of the P2Y (1) receptor in tissue factor-induced thrombin- dependent acute thromboembolism: studies in P2Y (1) -knockout mice and mice treated with a P2Y (1) antagonist. Circulation 2001; 103: 71823.
  • 9
    Leon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y (1) receptor-null mice. J Clin Invest 1999; 104: 17317.
  • 10
    Lenain N, Freund M, Leon C, Cazenave JP, Gachet C. Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y (1) receptor antagonist. J Thromb Haemost 2003; 1: 11449.DOI: 10.1046/j.1538-7836.2003.00144.x
  • 11
    Zhang FL, Luo L, Gustafson E, Lachowicz J, Smith M, Qiao X, Liu YH, Chen G, Pramanik B, Laz TM, Palmer K, Bayne M, Monsma FJ Jr. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J Biol Chem 2001; 276: 860815.DOI: 10.1074/jbc.M009718200
  • 12
    Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 2027.DOI: 10.1038/35051599
  • 13
    Ohlmann P, Laugwitz KL, Nurnberg B, Spicher K, Schultz G, Cazenave JP, Gachet C. The human platelet ADP receptor activates Gi2 proteins. Biochem J 1995; 312: 7759.
  • 14
    Jantzen HM, Milstone DS, Gousset L, Conley PB, Mortensen RM. Impaired activation of murine platelets lacking G alpha (i2). J Clin Invest 2001; 108: 47783.DOI: 10.1172/JCI200112818
  • 15
    Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19: 22815.
  • 16
    Savi P, Herbert JM. Pharmacology of Ticlopidine and Clopidogrel. Haematologica 2000; 85: 737.
  • 17
    Unterberger U, Moskvina E, Scholze T, Freissmuth M, Boehm S. Inhibition of adenylyl cyclase by neuronal P2Y receptors. Br J Pharmacol 2002; 135: 67384.
  • 18
    Simon J, Vigne P, Eklund KM, Michel AD, Carruthers AM, Humphrey PP, Frelin C, Barnard EA. Activity of adenosine diphosphates and triphosphates on a P2Y (T) -type receptor in brain capillary endothelial cells. Br J Pharmacol 2001; 132: 17382.
  • 19
    Takasaki J, Kamohara M, Saito T, Matsumoto M, Matsumoto S, Ohishi T, Soga T, Masushime H, Furuichi K. Molecular cloning of the platelet P2T (AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y (1) receptor. Mol Pharmacol 2001; 60: 4329.
  • 20
    Boyer JL, Lazarowski ER, Chen XH, Harden TK. Identification of a P2Y-purinergic receptor that inhibits adenylyl cyclase. J Pharmacol Exp Ther 1993; 267: 11406.
  • 21
    Jin J, Tomlinson W, Kirk IP, Kim YB, Humphries RG, Kunapuli SP. The C6–2B glioma cell P2Y (AC) receptor is pharmacologically and molecularly identical to the platelet P2Y (12) receptor. Br J Pharmacol 2001; 133: 5218.
  • 22
    Park HS, Hourani SM. Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adnosine 5-diphosphate (ADP) in human platelets. Br J Pharmacol 1999; 127: 135966.
  • 23
    Cusack NJ, Hourani SM. Adenosine 5-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors. Br J Pharmacol 1982; 76: 2217.
  • 24
    Cusack NJ, Hourani SM. Adenosine, adenine nucleotides, and platelet function. In: Adenosine and Adenine Nucleotides as Regulators of Cellular Function: Baton Rouge: CRC Press; 1991.
  • 25
    Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 2000; ; 362: 299309.DOI: 10.1007/s002100000309
  • 26
    Lazarowski ER, Homolya L, Boucher RC, Harden TK. Identification of an ecto-nucleoside diphosphokinase and its contribution to interconversion of P2 receptor agonists. J Biol Chem 1997; 272: 204027.DOI: 10.1074/jbc.272.33.20402
  • 27
    Hechler B, Vigne P, Leon C, Breittmayer JP, Gachet C, Frelin C. ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol Pharmacol 1998; 53: 72733.
  • 28
    Leon C, Hechler B, Vial C, Leray C, Cazenave JP, Gachet C. The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 1997; 403: 2630.DOI: 10.1016/S0014-5793(97)00022-7
  • 29
    Baurand A, Eckly A, Bari N, Leon C, Hechler B, Cazenave JP, Gachet C. Desensitization of the platelet aggregation response to ADP. differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost 2000; 84: 48491.
  • 30
    Palmer RK, Boyer JL, Schachter JB, Nicholas RA, Harden TK. Agonist action of adenosine triphosphates at the human P2Y1 receptor. Mol Pharmacol 1998; 54: 111823.
  • 31
    Kauffenstein G, Bergmeier W, Eckly A, Ohlmann P, Leon C, Cazenave JP, Nieswandt B. The P2Y (12) receptor induces platelet aggregation through weak activation of the alphaIIb beta3 integrin – a phosphoinositide 3- kinase-dependent mechanism. FEBS Lett 2001; 505: 28190.DOI: 10.1016/S0014-5793(01)02824-1
  • 32
    Cazenave JP, Hemmendinger S, Beretz A, Sutter-Bay A, Launay J. L'agrégation plaquettaire: outil d'investigation clinique et d'étude pharmacologique. Méthodologie Ann Biol Clin 1983; 41: 16779.
  • 33
    Macfarlane DE, Srivastava PC, Mills DC. 2-Methylthioadenosine[beta-32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J Clin Invest 1983; 71: 4208.
  • 34
    Lazarowski ER, Watt WC, Stutts MJ, Boucher RC, Harden TK. Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol 1995; 116: 161927.
  • 35
    Yasuoka K, Kawakita M, Kaziro Y. Interaction of adenosine-5′-O-(3-thiotriphosphate) with Ca2+,Mg2+-adenosine triphosphatase of sarcoplasmic reticulum. J Biochem (Tokyo) 1982; 91: 162937.
  • 36
    Mills DC. ADP receptors on platelets. Thromb Haemost 1996; 76: 83556.
  • 37
    Joseph SM, Buchakjian MR, Dubyak GR. Colocalization of ATP release sites and ecto-ATPase activity at the extracellular surface of human astrocytes. J Biol Chem 2003; 278: 2333142.
  • 38
    Gachet C, Cattaneo M, Ohlmann P, Hechler B, Lecchi A, Chevalier J, Cassel D, Mannucci PM, Cazenave JP. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 1995; 91: 43444.
  • 39
    Bodor ET, Waldo GL, Hooks SB, Corbitt J, Boyer JL, Harden TK. Purification and Functional Reconstitution of the Human P2Y12 Receptor. Mol Pharmacol 2003; 64: 12106.
  • 40
    Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally JI, Hunt SF, Kindon ND, Teobald BJ, Willis PA, Humphries RG, Leff P, Clegg JA, Smith JA, Tomlinson W. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999; 42: 21320.
  • 41
    Lazarowski ER, Boucher RC, Harden TK. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol Pharmacol 2003; 64: 78595.
  • 42
    Beigi R, Kobatake E, Aizawa M, Dubyak GR. Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase. Am J Physiol 1999; 276: C26778.